

FOR IMMEDIATE RELEASE

**HC Surgical Extends ASEAN Footprint –
Inks Exclusive Collaboration with The Prestige Hospital Co., Ltd.,
Cambodia**

Highlights

- **HC Surgical appointed as the consultancy service provider for The Prestige Hospital Co., Ltd. (“TPH”) endoscopy centre**
- **HCSS to provide certain exclusive medical services in TPH for a period of 3 years**
- **Anticipate to generate recurring revenue stream for HCSS**

Singapore, 13 January 2020 – Catalyst-listed **HC Surgical Specialists Limited (SGX:1B1)** (“**HCSS**”, or the “**Company**” and collectively with its subsidiaries, the “**Group**”) is pleased to announce that it has today, entered into an exclusive agreement (“**Agreement**”) with The Prestige Hospital Co., Ltd. (“**TPH**”), a company incorporated in Cambodia, which is valid for a term of 3 years upon commencement of the operations of the endoscopy centre, which is estimated to be on 1 March 2020 or such later date as may be agreed to in writing between both parties.

HCSS will provide consultancy services for the set-up of an endoscopy centre within TPH, in addition to providing medical services in TPH for a period of 3 years. This will create an additional revenue stream for the Group. The exclusive collaboration with TPH is strategically aligned with the Group’s long-term plans for regional expansion as HCSS continues to extend its footprint into a new market – Cambodia.

The Prestige Hospital Co., Ltd. has established itself as a first-of-its-kind integrated medical hub in Cambodia and the leading provider of high quality, tailored medical services with a strong medical team of foreign trained specialists and practices in place to ensure that its patients receive the highest level of international standard care. It offers comprehensive services for families with a specialisation in women



Incorporated in the Republic of Singapore
Registration No. 201533429G

and children's health. TPH also has partnerships with global hospital providers and provides access to specialised treatments in Singapore, Thailand and Canada.

Chief Executive Officer of HCSS, Dr. Heah Sieu Min commented, ***"We are extremely exhilarated and look forth to our exclusive collaboration with The Prestige Hospital as it marks our maiden foray into Cambodia which is a new market for us. We see this opportunity as a testament to our medical expertise and capabilities, which is in line with our growth strategy to fortify our presence in the region. We are on track with our expansion plans and will continue to keep a lookout for other potential synergistic collaborations locally and regionally."***

Executive Director of The Prestige Hospital Co., Ltd., Mr. Christopher Yeow added, ***"As the leading healthcare provider in Cambodia, we always seek to partner with the best in rendering high quality medical services to our patients. We believe HCSS, an established medical services group in Singapore, is well-positioned to provide value-added services to our hospital with their medical expertise and capabilities."***

– End –

About HC Surgical Specialists Limited

HC Surgical Specialists Limited ("HCSS") was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. HCSS, its subsidiaries and associated company is a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 16 clinics located throughout Singapore.

For more information, please visit HCSS's website at www.hcsurgicalspecialists.com.



Incorporated in the Republic of Singapore
Registration No. 201533429G

Investor Relations Contact:

Issued By : HC Surgical Specialists Limited

Media Contact : Ms Chan Hui Si | huisi@gem-comm.com

Investor Relations Contact : Ms Emily Choo | emily@gem-comm.com

This press release has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor") in compliance with Rules 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made, or reports contained in this press release.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.